Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-12-08
2009-11-10
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S051000, C514S274000, C536S028540, C544S243000, C544S314000
Reexamination Certificate
active
07615542
ABSTRACT:
The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1is H, an acyl group, a C1-C20alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nuleocoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (−)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R1is preferably H or a C2-C18acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.
REFERENCES:
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5852027 (1998-12-01), Liotta et al.
patent: 6350753 (2002-02-01), Belleau et al.
patent: 6855821 (2005-02-01), Du et al.
patent: 7119202 (2006-10-01), Belleau et al.
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published by Merck Research Laboratories, (1999), edited by Beers and Berkow, pp. 1312-1323.
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merch Research Laboratories, Ed. by Beers and Berkow, pp. 1132-1135.
Kim et al., “Asymmetric Synthesis of 1,3-Dioxolane-Pyrimidine Nucleosides and Their Anti-HIV Activity” Journal of Medicinal Chemistry (1992) vol. 35, pp. 1987-1995.
Chu et al.,J. Org. Chem. 1991, 56(23):6503-6505.
Choi et al,J. Am. Chem. Soc. 1991, 113:9377-9379.
Belen'kii, M.S. et al. “Multiple drug effect analysis with confidence interval”Antiviral Research25:1-11 (1994).
Buckheit, Jr., R.W. et al. “Characterization of an HIV-1 Isolate Displaying an Apparent Absence of Virion-Associated Reverse Transcriptase Activity”AIDS Research and Human Retroviruses7:295-302 (1991).
Chu, C.K. et al. “Asymmetric Synthesis of Enantiomerically Pure (-)-(1′R,4′R)-Dioxolane-thymine and Its Anti-HIV Activity.”Tetrahedron Letters32:3791-3794.
Chu Chung K.
Schinazi Raymond F.
Coleman Henry D.
Emory UNiversity
Jiang Shaojia Anna
Olson Eric S
Sapone William J.
LandOfFree
Dioxolane thymine and combinations for use against 3TC/AZT... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dioxolane thymine and combinations for use against 3TC/AZT..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dioxolane thymine and combinations for use against 3TC/AZT... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142327